J&J’s COVID-19 Vaccine Will Enter Phase 3 Testing, the Fourth To Reach That Stage
, the vaccine produced sufficient immune responses that could neutralize the virus in the lab, and early tests in people which began in mid-July produced similarly encouraging results, which Stoffels says the company will publish in coming weeks.
As with the other late-stage trials, this study will be supervised by the same data safety monitoring board, which will analyze the data regularly for safety signals and signs of effectiveness or futility.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Johnson & Johnson Covid-19 vaccine enters Phase 3 trial in U.S.The drugmaker's vaccine candidate is the fourth to enter final-phase human trials in the country.
Weiterlesen »
Administration Announces $200 million from CDC to Jurisdictions for COVID-19 Vaccine PreparednessThe Department of Health and Human Services (HHS) is announcing upcoming action by the Centers for Disease Control and Prevention (CDC) to provide $200 million to jurisdictions for COVID-19 vaccine preparedness.
Weiterlesen »
J&J kicks off final study of single-shot COVID-19 vaccine in 60,000 volunteersJohnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot COVID-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses.
Weiterlesen »
Johnson & Johnson’s Single-Shot COVID-19 Vaccine Moves to Final Trial StageJohnson & Johnson’s vaccine candidate boasts two major advantages over competitors already in Phase 3 trials: It only requires one shot, not two; and it does not need to be stored in subzero temperatures
Weiterlesen »